Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Eric Tatro

Gastroenterology Salem, OR Medical Doctor

NPI 1558821827 CMS profile 8145458

875 Oak St Se Ste C3010, Salem, OR 97301

Open in the dashboard

General payments

$2,422

103 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Tatro of Salem, OR is reported in the CMS Open Payments database as having received $2,422 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $754 30
2024 General $1,019 47
2023 General $558 22
2022 General $91 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Tatro
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eric Tatro were reported at $754. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eric Tatro Gastroenterology median Middle half National median
2019 $0 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $91 $448 $129–$1,270 $149
2023 $558 $533 $150–$1,390 $160
2024 $1,019 $605 $160–$1,606 $164
2025 $754 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $519 31 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $514 22 payments
  3. Janssen Biotech, Inc. $458 23 payments
  4. Ardelyx, Inc. $213 8 payments
  5. Madrigal Pharmaceuticals $195 3 payments
  6. Ferring Pharmaceuticals Inc. $152 3 payments
  7. Cook Medical LLC $148 1 payment
  8. Pfizer Inc. $69 4 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $63 3 payments
  10. Gilead Sciences, Inc. $43 2 payments
  11. Other $46 3 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,342 102 payments
  2. Education $80 1 payment
Products named General payments · program years 2022–2025
  1. STELARA $325 13 payments
  2. TREMFYA $306 17 payments
  3. SKYRIZI $282 14 payments
  4. ENTYVIO $254 10 payments
  5. GATTEX $237 11 payments
  6. IBSRELA $213 8 payments
  7. REZDIFFRA $195 3 payments
  8. RINVOQ $180 13 payments
  9. SIMPONI ARIA $173 7 payments
  10. SIMPONI $173 7 payments
  11. Other $739 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

131

Median for Internal Medicine: 777

Drug cost

$1,850

Median for Internal Medicine: $73,373

Branded share of claims

16.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pantoprazole Sodium Generic 70 $588
Omeprazole Generic 12 $441
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 22 $419
Dicyclomine Hcl Generic 27 $402

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $256
$256 — —
STELARA
  • Janssen Biotech, Inc. $181
$181 — —
IBSRELA
  • Ardelyx, Inc. $118
$118 — —
RINVOQ
  • AbbVie, Inc. $87
$87 — —
TREMFYA
  • Janssen Biotech, Inc. $81
$81 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record